ecco Archives - AudioMedica.com

Tagged: ecco

- in Oncology
- — 15 Feb, 2008
Oral Capecitabine: As Good As Fluorouracil Second Line for Metastatic Colorectal Cancer

David Cunningham
REFERENCE: Abstract 3012, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
DAVID CUNNINGHAM, Royal Marsden Hospital, London
The oral agent capeticabine is just as effective as fluorouracil for treating patients whose metastatic colorectal cancer
…
Read more
$Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone$
- in Oncology
- — 1 Feb, 2008
Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone

Cora Sternberg
REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
CORA STERNBERG, San Camillo and Forlanini Hospital, Rome
Satraplatin could provide a new option for patients with hormone refractory prostate cancer, by giving
…
Read more
- in Oncology
- — 16 Nov, 2007
Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Jean-Yves Douillard

Gordon McVie
REFERENCE: Abstracts: 6507 & 2LB, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
JEAN-YVES DOUILLARD, Centre René Gauducheau, Nante
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
The vinca alkaloid vinflunine and
…
Read more
$Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer$
- in Oncology
- — 2 Nov, 2007
Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer

Nicholas James

Gordon McVie
REFERENCE: Abstract: 3LB (Presidential Session), ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
NICHOLAS JAMES, Birmingham University
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
A new drug has improved overall survival
…
Read more
- in Oncology
- — 16 Oct, 2007
Neoadjuvant Trastuzumab: Marked Benefit in HER2-Positive Inflammatory Breast Cancer

Jose Baselga

Gordon McVie
REFERENCE: ABSTRACT 2030, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
JOSE BASELGA, Vall d’Hebron University Hospital, Barcelona
COMMENT: GORDON MCVIE, European Institute of Oncology, Milan
Neoadjuvant trastuzumab for patients with HER2-positive
…
Read more
- in Oncology
- — 1 Oct, 2007
Intraperitoneal Catumaxomab Prolongs Survival in Patients With Malignant Ascites from Ovarian Cancer

Markus Heiss
REFERENCE: ABSTRACT 5001, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
MARKUS HEISS, Klinikum Cologne, Merheim
For patients with malignant ascites as a result of ovarian cancer, a novel intraperitoneal therapy adding the trifunctional
…
Read more
- in ECCO 2005 · Oncology
- — 30 Oct, 2005
Breast Cancer: Further Support for Trastuzumab from Combined Analysis

Edward Romond
Edward Romond, University of Kentucky, Lexington
More data for trastuzumab comes from a combined analysis of two large, parallel trials: NSABP B-31 and NCCTG N9831. Both looked at adding trastuzumab to doxorubicin and cyclophosphamide followed by paclitaxel.
[audio:https://www.audiomedica.com/podcasting/ajo_13.8/02.edward_romond.mp3] …
Read more

Tagged: ecco

Oral Capecitabine: As Good As Fluorouracil Second Line for Metastatic Colorectal Cancer

Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone

Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer

Neoadjuvant Trastuzumab: Marked Benefit in HER2-Positive Inflammatory Breast Cancer

Intraperitoneal Catumaxomab Prolongs Survival in Patients With Malignant Ascites from Ovarian Cancer

Breast Cancer: Further Support for Trastuzumab from Combined Analysis

Sign up for AudioMedica.com news